Impact of sodium–glucose cotransporter 2 inhibitors on blood pressure DOI Creative Commons

James Reed

Vascular Health and Risk Management, Journal Year: 2016, Volume and Issue: Volume 12, P. 393 - 405

Published: Oct. 1, 2016

Abstract: SGLT2 inhibitors are glucose-lowering agents used to treat type 2 diabetes mellitus (T2DM). These target the kidney promote urinary glucose excretion, resulting in improved blood control. SGLT2-inhibitor therapy is also associated with weight loss and pressure (BP) lowering. Hypertension a common comorbidity patients T2DM, excess morbidity mortality. This review summarizes data on effect of marketed US (namely canagliflozin, dapagliflozin, or empagliflozin) BP T2DM. Boolean searches were conducted that included terms related hypertension for inhibitors, empagliflozin using PubMed, Google, Google Scholar. Data from numerous randomized controlled trials T2DM demonstrated clinically relevant reductions both systolic diastolic BP, assessed via seated office measurements 24-hour ambulatory monitoring. Observed lowering was not compensatory increases heart rate. Circadian rhythm maintained. The mechanism inhibitor-associated reduction fully understood, but assumed be osmotic diuresis natriuresis. Other factors may contribute include decreases body reduced arterial stiffness. Local inhibition renin–angiotensin–aldosterone system secondary increased delivery sodium juxtaglomerular apparatus during has been postulated. Although indicated as BP-lowering agents, modest observed provide an extra clinical advantage majority addition improving Keywords: pressure, empagliflozin, sodium–glucose cotransporter

Language: Английский

Type 2 diabetes mellitus DOI
Ralph A. DeFronzo, Ele Ferrannini, Leif Groop

et al.

Nature Reviews Disease Primers, Journal Year: 2015, Volume and Issue: 1(1)

Published: July 22, 2015

Language: Английский

Citations

2039
Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes DOI Creative Commons
Robert Ćhilton,

I. Tikkanen,

Christopher P. Cannon

et al.

Diabetes Obesity and Metabolism, Journal Year: 2015, Volume and Issue: 17(12), P. 1180 - 1193

Published: Sept. 7, 2015

To determine the effects of empagliflozin on blood pressure (BP) and markers arterial stiffness vascular resistance in patients with type 2 diabetes mellitus (T2DM).We conducted a post hoc analysis data from phase III trial T2DM hypertension receiving 12 weeks' four trials 24 (cohort 1, n = 823; cohort 2, 2477). BP was measured using 24-h monitoring 1) or seated office measurements 2).Empagliflozin reduced systolic (SBP) diastolic both cohorts (p < 0.001 vs placebo), without increasing heart rate. Empagliflozin pulse (PP; adjusted mean difference placebo 1: -2.3 mmHg; 2: mmHg), (MAP; -2.1 mmHg) double product -385 mmHg × bpm; -369 bpm) all p placebo. There trend towards reduction ambulatory index (AASI) 1 0.059 placebo). AASI not 2. Subgroup analyses showed that there were greater reductions PP baseline SBP 0.092). In MAP achieved higher 0.027) observed older 0.011).Empagliflozin had favourable resistance.

Language: Английский

Citations

447
A Review of Current Trends with Type 2 Diabetes Epidemiology, Aetiology, Pathogenesis, Treatments and Future Perspectives DOI Creative Commons
Josh Reed, Stephen C. Bain, Venkateswarlu Kanamarlapudi

et al.

Diabetes Metabolic Syndrome and Obesity, Journal Year: 2021, Volume and Issue: Volume 14, P. 3567 - 3602

Published: Aug. 1, 2021

Type 2 diabetes (T2D), which has currently become a global pandemic, is metabolic disease largely characterised by impaired insulin secretion and action. Significant progress been made in understanding T2D aetiology pathogenesis, discussed this review. Extrapancreatic pathology also summarised, demonstrates the highly multifactorial nature of T2D. Glucagon-like peptide (GLP)-1 an incretin hormone responsible for augmenting from pancreatic beta-cells during postprandial period. Given that native GLP-1 very short half-life, mimetics with much longer half-life have developed, are effective treatment option enhancing patients. Interestingly, there continual emerging evidence these therapies alleviate some post-diagnosis complications Additionally, shown to induce weight loss patients, suggesting they could be alternative bariatric surgery, procedure associated numerous complications. Current GLP-1-based all act as orthosteric agonists receptor (GLP-1R). it emerged GLP-1R allosteric binding sites developed test their therapeutic potential. Recent studies demonstrated potential bi- tri-agonists, target multiple hormonal receptors including GLP-1R, more effectively treat Improved aetiology/pathogenesis, coupled further elucidation both activity/targets mechanisms activation via different agonists, will likely provide better insight into

Language: Английский

Citations

296
Hypertension in Diabetes: An Update of Basic Mechanisms and Clinical Disease DOI Open Access
Guanghong Jia, James R. Sowers

Hypertension, Journal Year: 2021, Volume and Issue: 78(5), P. 1197 - 1205

Published: Oct. 4, 2021

Epidemiological studies have documented that insulin resistance and diabetes not only constitute metabolic abnormalities but also predispose to hypertension, vascular stiffness, associated cardiovascular disease. Meanwhile, excessive arterial stiffness impaired vasorelaxation, in turn, contribute worsening the development of diabetes. Molecular mechanisms promoting hypertension include inappropriate activation renin-angiotensin-aldosterone system sympathetic nervous system, mitochondria dysfunction, oxidative stress, systemic inflammation. This review highlights recent which uncovered new underlying for increased propensity association with These enhanced epithelial sodium channels, alterations extracellular vesicles their microRNAs, abnormal gut microbiota, renal sodium-glucose cotransporter activity, collectively covers socioeconomic factors currently recommended blood pressure targets related treatment strategies diabetic patients hypertension.

Language: Английский

Citations

236
Glomerular hyperfiltration DOI
Monica Cortinovis, Norberto Perico, Piero Ruggenenti

et al.

Nature Reviews Nephrology, Journal Year: 2022, Volume and Issue: 18(7), P. 435 - 451

Published: April 1, 2022

Language: Английский

Citations

120
Danuglipron (PF-06882961) in type 2 diabetes: a randomized, placebo-controlled, multiple ascending-dose phase 1 trial DOI
Aditi R. Saxena, Donal Gorman, Ryan M. Esquejo

et al.

Nature Medicine, Journal Year: 2021, Volume and Issue: 27(6), P. 1079 - 1087

Published: June 1, 2021

Language: Английский

Citations

107
Exercise training for patients with type 2 diabetes and cardiovascular disease: What to pursue and how to do it. A Position Paper of the European Association of Preventive Cardiology (EAPC) DOI Open Access
Hareld Kemps,

Nicolle Kränkel,

Marcus Dörr

et al.

European Journal of Preventive Cardiology, Journal Year: 2019, Volume and Issue: 26(7), P. 709 - 727

Published: Jan. 14, 2019

Patients with type 2 diabetes mellitus suffer from dysregulation of a plethora cardiovascular and metabolic functions, including dysglycaemia, dyslipidaemia, arterial hypertension, obesity reduced cardiorespiratory fitness. Exercise training has the potential to improve many these such as insulin sensitivity, lipid profile, vascular reactivity fitness, particularly in patients comorbidities, that suffered an acute myocardial infarction, or after coronary intervention percutaneous artery bypass grafting. The present position paper aims provide recommendations for prescription exercise both disease. first part discusses relevance practical applicability treatment targets may be pursued, failure respond targets. second provides on contents methods prescribe tailored well optimal preparation dealing barriers risks specific cardiac comorbidity.

Language: Английский

Citations

115
Hypertension with diabetes mellitus: significance from an epidemiological perspective for Japanese DOI
Yukako Tatsumi, Takayoshi Ohkubo

Hypertension Research, Journal Year: 2017, Volume and Issue: 40(9), P. 795 - 806

Published: July 13, 2017

Language: Английский

Citations

113
High prevalence of diabetes mellitus, hypertension and obesity among persons with a recorded diagnosis of intellectual disability or autism spectrum disorder DOI Open Access
Eva Flygare Wallén,

G Ljunggren,

Axel C. Carlsson

et al.

Journal of Intellectual Disability Research, Journal Year: 2017, Volume and Issue: 62(4), P. 269 - 280

Published: Dec. 26, 2017

Abstract Background Obesity and lack of physical activity are frequently reported in persons with intellectual disability (ID) or autism spectrum disorder (ASD). We hypothesised a higher prevalence diabetes hypertension this population. Method used administrative data for all primary specialist outpatient inpatient healthcare consultations people at least one recorded diagnosis mellitus, obesity from 1998 to 2015. Data were drawn the central database Stockholm County, Sweden. It was not possible separate type 1 2 diabetes. stratified 26 988 individuals IDs ASD into three groups, Down syndrome treated separately, compared these groups 996 140 general Results Compared population, men women ID/ASD had 1.6–3.4‐fold age‐adjusted odds having registered exception among syndrome. A only more common than Conclusions Diabetes blood pressure health screening, along efforts prevent development already childhood, necessary ASD. believe that there is need adapted community‐based promotion programmes ensure equitable populations.

Language: Английский

Citations

100
Diabetes and Cardiovascular Disease: an Update DOI

Rajaa Almourani,

Bhavana Chinnakotla,

Richa Patel

et al.

Current Diabetes Reports, Journal Year: 2019, Volume and Issue: 19(12)

Published: Dec. 1, 2019

Language: Английский

Citations

96